ANZSREI consensus statement on elective oocyte cryopreservation

Abstract

BK and MC are shareholders in Virtus Health. CB owns a facility offering oocyte cryopreservation.

Age-related fertility decline and elective oocyte cryopreservation: Knowledge, attitudes and practices in a pilot study of general practitioners

“…24 Earlier discussion facilitates earlier, more effective EOC treatment. 2 However, participants with reservations about EOC were less likely to discuss EOC with their younger patients. It may take women many years to decide to freeze oocytes (Sandhu S, Hickey M, Braat S, Lew R, Peate M, unpublished), and given the ultimate importance of timing for optimal efficacy, women need to be aware of EOC from a relatively early age.…”

“…1 The prevalence of female infertility increases with advancing age because of the biological limits of oocyte metabolism and function. 2 The risk of female infertility rises from 6% at age 20-24 years to 64% at age 40-44 years, 3 with the most significant reduction occurring from the ages of 37-38 years. 4 In this context, growing numbers of women and couples are being treated for age-related infertility.…”

“…With encouraging data emerging on safety and efficacy, the Australian and New Zealand Society for Reproductive Endocrinology and Infertility (ANZSREI) in 2019 described EOC as an ethically permissible, safe, well-established mainstream treatment. 2 The public are generally aware of EOC and ovarian reserve testing and support it. [9][10][11][12] Ovarian reserve testing, requisite to planning EOC, 4 includes measurement of anti-Müllerian hormone (AMH) and antral follicle count (AFC), which are helpful in assessing oocyte quantity and enable assisted reproductive technology (ART) practitioners to tailor treatment.…”

Assessment of female fertility in the general practice setting

“…27 Infertility is most prevalent in women aged >35 years and results in significant burden of disease. 28 The advent of vitrification technology means that cryopreserved oocytes have survival rates >84% and comparable in vitro fertilisation outcomes to fresh oocytes. 29 Increasingly, women are considering elective oocyte cryopreservation to allow an opportunity to conceive biologically related children at a later age.…”

The case for mild stimulation for IVF: recommendations from The International Society for Mild Approaches in Assisted Reproduction

“…Anticipated lower risk-profile. (Doyle, et al, 2016, Lew, et al, 2019 Oocyte donation cycles: Oocyte donors do not need to produce a high number of oocytes to donate to a single recipient to achieve a success.…”